News Gilead buys cell therapy partner Arcellx for up to $7.8bn Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.
News Head-to-head trial dents Novo Nordisk's obesity hopes Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.
News Grail's multi-cancer test fluffs its lines in UK trial Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.
News Ex-Novartis CMO John Tsai joins Daiichi Sankyo Daiichi Sankyo has named John Tsai as its new global head of R&D, replacing Ken Takeshita, who is stepping down after five years in the role.
News MSD and Mayo Clinic team up on AI drug discovery MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.
News Number of UK biotech companies rising, says report A report has found that the number of life sciences companies domiciled in the UK has grown by nearly a quarter in the last few years.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.